Is Wall Street Bullish or Bearish on Vertex Pharmaceuticals Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 29 2024
0mins
Should l Buy VRTX?
Source: NASDAQ.COM
Company Performance: Vertex Pharmaceuticals has shown strong stock performance, gaining 32.7% over the past year, outperforming both the S&P 500 and the VanEck Biotech ETF, driven by successful product launches and anticipated FDA decisions.
Analyst Ratings and Forecasts: The consensus among analysts is a "Moderate Buy" for VRTX, with a mean price target of $520.48, indicating potential upside, while RBC Capital maintains a "Hold" rating with a price target of $451.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise
22 Analyst Rating
17 Buy
5 Hold
0 Sell
Strong Buy
Current: 474.270
Low
414.00
Averages
515.88
High
604.00
Current: 474.270
Low
414.00
Averages
515.88
High
604.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Esiason Father-Son Duo Champions Cystic Fibrosis Awareness
- Family Struggle: In 1993, NFL quarterback Boomer Esiason's son Gunnar was diagnosed with cystic fibrosis, a condition then viewed as fatal for children, prompting the Esiason family to become leading advocates, raising nearly $200 million through the Boomer Esiason Foundation for research and patient support.
- Clinical Trial Participation: Gunnar participated in a clinical trial for the drug Trikafta in 2018, developed by Vertex Pharmaceuticals, which received FDA fast track review and was approved in 2019; he experienced significant health improvements during the trial, marking a major shift in his quality of life.
- Raising Public Awareness: The Esiason father-son duo shared their journey at the CNBC Cares Summit, emphasizing the importance of personal stories in raising public awareness about cystic fibrosis, which is crucial for advancing research and treatment, especially when the disease is often overlooked.
- Foundation's Impact: The Boomer Esiason Foundation not only provides financial support for cystic fibrosis patients but has also helped increase life expectancy, with many patients now living into their sixties, significantly changing perceptions of the disease that was once thought to be fatal in childhood.
See More
Esiason Father-Son Duo's Fight Against Cystic Fibrosis
- Foundation Establishment: After learning of his son Gunnar's cystic fibrosis diagnosis, Boomer Esiason quickly founded the Boomer Esiason Foundation, which has raised nearly $200 million to support CF research and patient assistance, significantly enhancing public awareness and attention to the disease.
- Clinical Trial Participation: Gunnar participated in the clinical trial for Vertex Pharmaceuticals' Trikafta in 2018, which received fast track review by the FDA and was approved in 2019, leading to unprecedented health improvements for Gunnar and marking a significant breakthrough in CF treatment.
- Quality of Life Improvement: Following treatment with Trikafta, Gunnar experienced newfound freedom, allowing him to engage in more activities, including hockey games, demonstrating the positive impact of the new drug on patient quality of life and altering his outlook on the future.
- Advocacy and Education: The Esiason father-son duo actively advocates for cystic fibrosis awareness and research through media and public events, promoting societal understanding of this rare disease and helping more families access support and resources.
See More
Analysis of Gene Editing Drug Market Prospects
- Gene Editing Breakthrough: Vertex Pharmaceuticals' collaboration with CRISPR Therapeutics led to the approval of Casgevy, the first gene-editing drug targeting sickle cell disease and transfusion-dependent beta-thalassemia, marking a significant advancement in gene therapy, although market revenue remains limited.
- Cost Challenges: With a treatment cost of $2.2 million in the U.S., the complex administration process and high expenses make it difficult for insurance companies to adopt, thereby restricting market penetration and patient accessibility, impacting the widespread application of gene editing drugs.
- Market Competition Analysis: CRISPR Therapeutics currently has only Casgevy as its approved drug and continues to face net losses, while Vertex boasts a diverse product lineup that enables stable sales and profits, demonstrating stronger market competitiveness and investment appeal.
- Future Development Potential: While CRISPR Therapeutics presents high return opportunities, especially if its CTX310 drug is approved to rapidly improve treatment for high cholesterol patients, the associated clinical research risks are significant, making it suitable for investors with higher risk tolerance.
See More
Investment Outlook in Gene Editing Market
- CRISPR Challenges: CRISPR Therapeutics faces significant challenges as its revolutionary drug Casgevy, approved for treating rare blood disorders, has not generated substantial revenue due to its high treatment cost of $2.2 million and the fact that it only has one approved product, leading to ongoing net losses.
- Vertex's Robust Business: In contrast, Vertex Pharmaceuticals boasts a diverse product lineup that generates consistent sales and profits, making it a safer investment option, especially as gene-editing therapies struggle for widespread acceptance among insurers.
- Market Potential: CRISPR Therapeutics is developing CTX310, which could provide a rapid treatment for lowering LDL cholesterol; if successful, it could significantly boost the company's stock price over the next decade, despite the risk of clinical trial failures.
- Investor Risk Assessment: While CRISPR Therapeutics offers high upside potential, it also carries considerable volatility, making it suitable for risk-tolerant investors, whereas Vertex provides more stable returns, appealing to risk-averse investors.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
CRISPR Therapeutics: Potential and Challenges in Gene Editing
- Therapeutic Progress: CRISPR's gene-editing therapy Casgevy was approved in 2023 for treating sickle cell disease and transfusion-dependent beta thalassemia, showcasing its revolutionary potential in healthcare.
- High Treatment Costs: Despite Casgevy's staggering price of $2.2 million, healthcare experts justify this cost due to its one-time treatment nature, which could save patients time and money in the long run.
- Financial Challenges: CRISPR reported a net loss of $581.6 million in 2025, an increase from the $366.3 million loss in 2024, highlighting the significant expenditure pressures the company faces as it rolls out Casgevy.
- Strong Cash Position: As of the end of last year, CRISPR had approximately $2 billion in cash and marketable securities, indicating that despite its losses, the company is not at immediate risk of running out of funds, maintaining long-term growth potential.
See More
Esiason Father-Son Duo Champions Cystic Fibrosis Awareness
- Family Struggle: In 1993, NFL quarterback Boomer Esiason's son Gunnar was diagnosed with cystic fibrosis, a condition then viewed as fatal for children, prompting the Esiason family to become leading advocates, raising nearly $200 million through the Boomer Esiason Foundation for research and patient support.
- Clinical Trial Participation: Gunnar participated in a clinical trial for the drug Trikafta in 2018, developed by Vertex Pharmaceuticals, which received FDA fast track review and was approved in 2019; he experienced significant health improvements during the trial, marking a major shift in his quality of life.
- Raising Public Awareness: The Esiason father-son duo shared their journey at the CNBC Cares Summit, emphasizing the importance of personal stories in raising public awareness about cystic fibrosis, which is crucial for advancing research and treatment, especially when the disease is often overlooked.
- Foundation's Impact: The Boomer Esiason Foundation not only provides financial support for cystic fibrosis patients but has also helped increase life expectancy, with many patients now living into their sixties, significantly changing perceptions of the disease that was once thought to be fatal in childhood.
See More
Esiason Father-Son Duo's Fight Against Cystic Fibrosis
- Foundation Establishment: After learning of his son Gunnar's cystic fibrosis diagnosis, Boomer Esiason quickly founded the Boomer Esiason Foundation, which has raised nearly $200 million to support CF research and patient assistance, significantly enhancing public awareness and attention to the disease.
- Clinical Trial Participation: Gunnar participated in the clinical trial for Vertex Pharmaceuticals' Trikafta in 2018, which received fast track review by the FDA and was approved in 2019, leading to unprecedented health improvements for Gunnar and marking a significant breakthrough in CF treatment.
- Quality of Life Improvement: Following treatment with Trikafta, Gunnar experienced newfound freedom, allowing him to engage in more activities, including hockey games, demonstrating the positive impact of the new drug on patient quality of life and altering his outlook on the future.
- Advocacy and Education: The Esiason father-son duo actively advocates for cystic fibrosis awareness and research through media and public events, promoting societal understanding of this rare disease and helping more families access support and resources.
See More
Analysis of Gene Editing Drug Market Prospects
- Gene Editing Breakthrough: Vertex Pharmaceuticals' collaboration with CRISPR Therapeutics led to the approval of Casgevy, the first gene-editing drug targeting sickle cell disease and transfusion-dependent beta-thalassemia, marking a significant advancement in gene therapy, although market revenue remains limited.
- Cost Challenges: With a treatment cost of $2.2 million in the U.S., the complex administration process and high expenses make it difficult for insurance companies to adopt, thereby restricting market penetration and patient accessibility, impacting the widespread application of gene editing drugs.
- Market Competition Analysis: CRISPR Therapeutics currently has only Casgevy as its approved drug and continues to face net losses, while Vertex boasts a diverse product lineup that enables stable sales and profits, demonstrating stronger market competitiveness and investment appeal.
- Future Development Potential: While CRISPR Therapeutics presents high return opportunities, especially if its CTX310 drug is approved to rapidly improve treatment for high cholesterol patients, the associated clinical research risks are significant, making it suitable for investors with higher risk tolerance.
See More
Investment Outlook in Gene Editing Market
- CRISPR Challenges: CRISPR Therapeutics faces significant challenges as its revolutionary drug Casgevy, approved for treating rare blood disorders, has not generated substantial revenue due to its high treatment cost of $2.2 million and the fact that it only has one approved product, leading to ongoing net losses.
- Vertex's Robust Business: In contrast, Vertex Pharmaceuticals boasts a diverse product lineup that generates consistent sales and profits, making it a safer investment option, especially as gene-editing therapies struggle for widespread acceptance among insurers.
- Market Potential: CRISPR Therapeutics is developing CTX310, which could provide a rapid treatment for lowering LDL cholesterol; if successful, it could significantly boost the company's stock price over the next decade, despite the risk of clinical trial failures.
- Investor Risk Assessment: While CRISPR Therapeutics offers high upside potential, it also carries considerable volatility, making it suitable for risk-tolerant investors, whereas Vertex provides more stable returns, appealing to risk-averse investors.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
CRISPR Therapeutics: Potential and Challenges in Gene Editing
- Therapeutic Progress: CRISPR's gene-editing therapy Casgevy was approved in 2023 for treating sickle cell disease and transfusion-dependent beta thalassemia, showcasing its revolutionary potential in healthcare.
- High Treatment Costs: Despite Casgevy's staggering price of $2.2 million, healthcare experts justify this cost due to its one-time treatment nature, which could save patients time and money in the long run.
- Financial Challenges: CRISPR reported a net loss of $581.6 million in 2025, an increase from the $366.3 million loss in 2024, highlighting the significant expenditure pressures the company faces as it rolls out Casgevy.
- Strong Cash Position: As of the end of last year, CRISPR had approximately $2 billion in cash and marketable securities, indicating that despite its losses, the company is not at immediate risk of running out of funds, maintaining long-term growth potential.
See More
